Adjuvant immunotherapy improves disease-free survival in residual esophageal squamous cell carcinoma

Across 2,090 patients with residual esophageal squamous cell carcinoma, adjuvant immunotherapy was associated with improved disease-free survival, while overall survival benefit remained uncertain.

KEY POINTS

  • This systematic review and meta-analysis included 12 studies and 2,090 patients with esophageal squamous cell carcinoma (ESCC) who had residual pathological disease after neoadjuvant treatment and curative-intent esophagectomy. 1,028 patients received adjuvant immune checkpoint inhibitors (ICIs) and 1,062 received no adjuvant treatment. The included studies, published between 2021 and 2026, primarily originated from East Asia and encompassed heterogeneous neoadjuvant chemotherapy, chemoradiotherapy, and immunochemotherapy regimens.
  • Adjuvant ICIs were associated with better overall survival in the primary pooled analysis. Across eight studies reporting time-to-event estimates, the pooled mortality hazard ratio was 0.49 (95% CI 0.33–0.72; p=0.0027), with moderate heterogeneity (I²=41.1%). Landmark overall survival also favored immunotherapy, with risk ratios of 1.10 at 12 months, 1.20 at 24 months, and 1.23 at 36 months. These estimates represent pooled associations rather than a single randomized treatment effect.
  • The overall survival association was no longer statistically significant after restricting the analysis to stronger comparative evidence. A sensitivity analysis including one randomized trial and three observational studies with adjusted estimates yielded HR 0.46 (95% CI 0.16–1.35; p=0.105). The substantially wider confidence interval and increased heterogeneity indicate that the magnitude and certainty of any overall survival benefit remain unresolved.
  • Disease-free survival consistently favored adjuvant immunotherapy. Across ten studies, the pooled hazard ratio for recurrence or death was 0.60 (95% CI 0.41–0.88; p=0.013), although heterogeneity was substantial (I²=59.8%). Importantly, the association persisted in the restricted analysis of two randomized trials and adjusted observational estimates, with HR 0.57 (95% CI 0.35–0.92; p=0.027). At 36 months, the pooled disease-free survival risk ratio was 1.22 (95% CI 1.06–1.40).
  • The type of neoadjuvant treatment did not establish a reliable predictor of adjuvant immunotherapy benefit. Exploratory analyses suggested numerically larger effects in patients previously receiving chemotherapy alone, but subgroup comparisons for overall survival and disease-free survival hazard ratios were not statistically significant. Individual subgroups contained few studies, with inconsistent molecular and pathological risk characterization. Consequently, these findings cannot support different postoperative ICI recommendations based solely on the preceding neoadjuvant regimen.
  • Important methodological limitations affect interpretation. Most included studies were retrospective, and treatment assignment could reflect postoperative recovery, performance status, residual tumor burden, or other prognostic differences. Potential immortal-time bias was especially relevant when survival was measured from surgery but immunotherapy classification depended on subsequently receiving treatment. Toxicity, treatment discontinuation, quality of life, and PD-L1 status were inconsistently reported, preventing a reliable pooled assessment of treatment harms or biomarker-defined benefit.
  • The findings extend, but do not replace, the randomized evidence from CheckMate 577. That trial established a disease-free survival advantage for adjuvant nivolumab after neoadjuvant chemoradiotherapy and surgery in patients with residual esophageal or gastroesophageal junction cancer. The present ESCC-focused synthesis provides supportive evidence for disease-free survival benefit, but cannot establish equivalent effectiveness across different prior treatment regimens or confirm an overall survival advantage.

CLINICAL TAKEAWAY

Adjuvant immune checkpoint inhibition is associated with improved disease-free survival in patients with residual esophageal squamous cell carcinoma following neoadjuvant treatment and surgery. However, the apparent overall survival benefit becomes statistically uncertain when analysis is restricted to randomized and adjusted observational evidence. These findings support established postoperative immunotherapy indications while highlighting the need for prospective studies addressing treatment selection after different neoadjuvant regimens.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction